Literature DB >> 25180273

Intraoperative parathyroid hormone monitoring in neonatal severe primary hyperparathyroidism.

Emilio García-García1, Inmaculada Domínguez-Pascual2, Mercedes Requena-Díaz2, Rosa Cabello-Laureano2, Israel Fernández-Pineda2, María J Sánchez-Martín2.   

Abstract

Neonatal severe primary hyperparathyroidism presents in the first days of life with severe life-threatening hypercalcemia. It is associated with an inactivating homozygous mutation of the calcium sensing receptor gene. Total parathyroidectomy is the treatment of choice, so the surgeon must identify all the parathyroid tissue, including supernumerary and ectopic glands. We present the case of an infant who underwent total parathyroidectomy at age 4 months in which intraoperative parathyroid hormone monitoring provided immediate confirmation of surgical cure.
Copyright © 2014 by the American Academy of Pediatrics.

Entities:  

Keywords:  hypercalcemia; neonatal severe primary hyperparathyroidism; parathyroid hormone

Mesh:

Substances:

Year:  2014        PMID: 25180273     DOI: 10.1542/peds.2013-3668

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

1.  Neonatal Severe Primary Hyperparathyroidism: A Series of Four Cases and their Long-term Management in India.

Authors:  Dhalapathy Sadacharan; Shriraam Mahadevan; Smitha S Rao; A Prem Kumar; S Swathi; Senthil Kumar; Subramanian Kannan
Journal:  Indian J Endocrinol Metab       Date:  2020-04-30

2.  A Case of Neonatal Severe Hyperparathyroidism: Challenges in Management.

Authors:  Priyanka Gupta; Shafat Ahmad Tak; Arun Viswanath S; Raiz Ahmad Misgar; Sandeep Agarwala; Vandana Jain; Rajni Sharma
Journal:  Indian J Pediatr       Date:  2022-04-05       Impact factor: 5.319

3.  Case report: acute clinical presentation and neonatal management of primary hyperparathyroidism due to a novel CaSR mutation.

Authors:  Manuela Capozza; Iolanda Chinellato; Vito Guarnieri; Natascia Di Lorgi; Maria Accadia; Cristina Traggiai; Girolamo Mattioli; Antonio Di Mauro; Nicola Laforgia
Journal:  BMC Pediatr       Date:  2018-10-30       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.